Oakville - Cardiol Therapeutics Inc. (TSX: CRDL; OTCQX: CRTPF) ('Cardiol' or the 'Company'), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it will webcast the Company's virtual Annual General Meeting of Shareholders (the 'AGM') on June 1, 2020, at 4:30 p.m. EDT.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (TSX: CRDL; OTCQX: CRTPF) is focused on producing pharmaceutical cannabidiol (CBD) products and developing innovative therapies for heart diseases, including acute myocarditis and other causes of heart failure. The Company's lead product, CardiolRx, is formulated to be the most consistent cannabidiol formulation on the market. CardiolRx is pharmaceutically produced, manufactured under cGMP, and is THC free (

(C) 2020 Electronic News Publishing, source ENP Newswire